NASDAQ:LQDA - Liquidia Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 75.44 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.17 (6.34%)

This chart shows the closing price for LQDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Liquidia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LQDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LQDA

Analyst Price Target is $5.00
▲ +75.44% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 75.44% upside from the last price of $2.85.

This chart shows the closing price for LQDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Liquidia. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2021HC WainwrightReiterated RatingBuy$6.00High
3/23/2021Needham & Company LLCLower Price TargetBuy$6.00 ➝ $5.00Medium
12/4/2020HC WainwrightInitiated CoverageBuy$6.00High
11/30/2020WedbushReiterated RatingHold$4.00High
11/20/2020WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $4.00High
10/15/2020WedbushLower Price TargetOutperform$38.00 ➝ $20.00High
7/7/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
7/7/2020WedbushReiterated RatingBuy$38.00Low
6/12/2020WedbushReiterated RatingBuy$41.00High
5/13/2020WedbushReiterated RatingBuy$41.00Medium
5/6/2020CowenReiterated RatingOutperform$40.00Medium
5/3/2020WedbushReiterated RatingBuy$41.00Low
4/8/2020WedbushBoost Price TargetOutperform$37.00 ➝ $41.00High
3/11/2020WedbushReiterated RatingBuy$37.00High
3/11/2020Needham & Company LLCReiterated RatingBuy$30.00High
1/27/2020WedbushReiterated RatingBuy$37.00Low
12/25/2019WedbushLower Price TargetOutperform$50.00 ➝ $37.00High
11/15/2019WedbushReiterated RatingBuy$50.00Low
6/28/2019WedbushReiterated RatingBuy$50.00High
5/2/2019WedbushReiterated RatingBuyHigh
4/8/2019WedbushReiterated RatingBuy$49.00Medium
3/26/2019WedbushReiterated RatingBuy$48.00 ➝ $49.00Low
3/12/2019WedbushBoost Price TargetOutperform$47.00 ➝ $48.00Low
1/16/2019WedbushReiterated RatingBuy$47.00High
11/28/2018WedbushBoost Price TargetOutperform$28.00 ➝ $47.00Low
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$27.00Medium
11/1/2018WedbushBoost Price TargetOutperform ➝ Buy$26.00 ➝ $28.00High
10/31/2018Needham & Company LLCSet Price TargetBuy$32.00Medium
10/31/2018CowenSet Price TargetBuy$40.00High
9/4/2018WedbushInitiated CoverageOutperform ➝ Outperform$26.00Medium
8/20/2018CowenInitiated CoverageOutperform$40.00High
8/20/2018Jefferies Financial GroupInitiated CoverageBuy$22.00High
8/20/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
(Data available from 6/24/2016 forward)
Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $2.85
Low: $2.63
High: $2.86

50 Day Range

MA: $2.79
Low: $2.53
High: $3.11

52 Week Range

Now: $2.85
Low: $2.34
High: $12.10


515,657 shs

Average Volume

961,581 shs

Market Capitalization

$148.12 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Liquidia?

The following Wall Street research analysts have issued reports on Liquidia in the last twelve months: HC Wainwright, Needham & Company LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for LQDA.

What is the current price target for Liquidia?

3 Wall Street analysts have set twelve-month price targets for Liquidia in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 86.6%. HC Wainwright has the highest price target set, predicting LQDA will reach $6.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $4.00 for Liquidia in the next year.
View the latest price targets for LQDA.

What is the current consensus analyst rating for Liquidia?

Liquidia currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LQDA will outperform the market and that investors should add to their positions of Liquidia.
View the latest ratings for LQDA.

What other companies compete with Liquidia?

How do I contact Liquidia's investor relations team?

Liquidia's physical mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company's listed phone number is (919) 328-4400 and its investor relations email address is [email protected] The official website for Liquidia is